glp 1 inhibitors weight loss GLP-1 receptor agonists Glucagon-like peptide-1 receptor agonists and

FDA Safety Announcement: Soliqua FDA Safety Label Change and Revised Drug Label Trulicity (active ingredient: dulaglutide) subcutaneous injection Initial FDA Approval: 2014 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting

Pricing can shift depending on the dose

A healthy eating plan of protein, vegetables and fruits is recommended

A recent analysis indicates that these drugs weaken the usual link between impulsive tendencies and aggressive actions

As research continues, more will emerge on how it compares and fits in with other treatments